Expert Call:
(86) 23-86916205
The Issues
Developing high-performance monoclonal & polyclonal antibodies for in vitro diagnostic (IVD) applications faces widespread industrial bottlenecks constraining reagent developers globally.
First, in-house antibody R&D requires long lead times, costly laboratory equipment and seasoned immunology teams, which imposes unaffordable capital pressure on mid-sized IVD startups and biotech enterprises lacking full-stack lab infrastructure. Many diagnostic brands struggle to obtain qualified antigen-specific polyclonal antisera with consistent titer, while hybridoma screening for monoclonal antibodies often suffers from low positive clone acquisition rate, leading to repeated R&D failures and delayed IVD kit listing schedules.
Second, lot-to-lot consistency is a core pain point for IVD raw material antibodies. Unstandardized animal immunization protocols and crude downstream purification frequently cause unstable antibody affinity & specificity, directly resulting in inconsistent diagnostic test line performance, failed CE/US FDA verification and costly product recall risks for finished IVD products.
Additionally, scaling from lab-scale small-batch antibody expression to GMP-compliant mass production brings massive technical barriers. Most biotech clients lack cleanroom production conditions and validated purification workflows, making it difficult to realize stable bulk antibody supply for commercialized diagnostic products.
First, in-house antibody R&D requires long lead times, costly laboratory equipment and seasoned immunology teams, which imposes unaffordable capital pressure on mid-sized IVD startups and biotech enterprises lacking full-stack lab infrastructure. Many diagnostic brands struggle to obtain qualified antigen-specific polyclonal antisera with consistent titer, while hybridoma screening for monoclonal antibodies often suffers from low positive clone acquisition rate, leading to repeated R&D failures and delayed IVD kit listing schedules.
Second, lot-to-lot consistency is a core pain point for IVD raw material antibodies. Unstandardized animal immunization protocols and crude downstream purification frequently cause unstable antibody affinity & specificity, directly resulting in inconsistent diagnostic test line performance, failed CE/US FDA verification and costly product recall risks for finished IVD products.
Additionally, scaling from lab-scale small-batch antibody expression to GMP-compliant mass production brings massive technical barriers. Most biotech clients lack cleanroom production conditions and validated purification workflows, making it difficult to realize stable bulk antibody supply for commercialized diagnostic products.
The Approach
As a professional IVD-focused CDMO service provider, we provide full-process custom monoclonal & polyclonal antibody preparation services covering target antigen processing, host animal immunization operated within certified controlled animal facility and dedicated antibody development laboratory, hybridoma construction, positive clone screening and GMP-compliant downstream purification.
For polyclonal antibody development, we select host animals including rabbit, goat and sheep, customize tiered immunization schedules based on antigen immunogenicity, conduct periodic serum titer detection and adopt multi-step affinity chromatography to harvest high-purity target-specific antisera. All animal-related procedures for polyclonal antibody development follow international animal welfare standards and are implemented at certified ethics-compliant controlled animal facilities.
For monoclonal antibody projects, our standardized pipeline contains cell fusion, limiting dilution screening, stable hybridoma subcloning, upstream cell culture optimization and fine purification. All production activities follow ISO13485 quality management standards with full traceable batch documents to assist clients’ subsequent IVD diagnostic reagent regulatory filing.
We support dual cooperation modes: small-scale customized R&D for early-stage reagent verification and turnkey bulk CDMO manufacturing for commercial mass production to match different project progress.
For polyclonal antibody development, we select host animals including rabbit, goat and sheep, customize tiered immunization schedules based on antigen immunogenicity, conduct periodic serum titer detection and adopt multi-step affinity chromatography to harvest high-purity target-specific antisera. All animal-related procedures for polyclonal antibody development follow international animal welfare standards and are implemented at certified ethics-compliant controlled animal facilities.
For monoclonal antibody projects, our standardized pipeline contains cell fusion, limiting dilution screening, stable hybridoma subcloning, upstream cell culture optimization and fine purification. All production activities follow ISO13485 quality management standards with full traceable batch documents to assist clients’ subsequent IVD diagnostic reagent regulatory filing.
We support dual cooperation modes: small-scale customized R&D for early-stage reagent verification and turnkey bulk CDMO manufacturing for commercial mass production to match different project progress.
The Benefits
Our standardized antibody CDMO system brings tangible cost, cycle and quality advantages to IVD raw material developers throughout custom antibody development and mass production.
Reduce total antibody development lead time by 35%–50% versus in-house R&D: our mature validated technical protocols eliminate redundant repeated experiments and accelerate customers’ IVD kit R&D and market launch progress.
Secure stable batch-consistent antibody indexes via standardized full-process control: unified immunization, culture and purification parameters stabilize antibody affinity and specificity to avoid finished diagnostic product performance deviation.
Support flexible output scaling from mg lab batches to kg commercial bulk orders: clients cut substantial upfront capital expenditure on factory and lab construction while obtaining long-term stable diagnostic antibody raw material supply.
Supporting Our Communities to Build Positive, Safe & Clear Patient Focused Culture.
Backed by standardized immunology workflows and ISO13485 quality management, we supply reliable custom monoclonal & polyclonal antibody raw materials to global IVD manufacturers, underpinning stable finished IVD kit performance and steady batch consistency of diagnostic raw materials worldwide.
Tips, News & Updates
CDMO Custom Development of Test Kits: From Assay Concept to Scalable IVD Manufacturing
CDMO custom development of test kits provides diagnostic companies with a structured route from an initial assay concept to a reproducible, manufacturable and commercially viable in vitro diagnostic product. Instead of outsourcin...
Quick Contact
If you have any questions or need help, feel free to contact with our team.
2F, Science & Technology Incubation Building, Chongqing Banan International Biocity,China